{"doi":"10.1369/jhc.2010.955765","title":"Phosphorylation of Fascin Decreases the Risk of Poor Survival in Patients With Esophageal Squamous Cell Carcinoma","abstract":"<jats:p>Phosphorylation of fascin at serine 39 (phospho-S39-fascin) could inhibit its actin-binding and actin-bundling activities and decrease filopodia formation. However, the relationship between phospho-S39-fascin expression and clinicopathological parameters in tumors is still unknown. Here, Western blot analysis and IHC applied to tissue microarray technology were performed to examine the expression status of non-phosphorylated fascin (fascin) and phospho-S39-fascin and their impacts on the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Fascin and phospho-S39-fascin expressions were tested by cytoplasmic staining. Among the 254 patients, 90 cases showed high expression of fascin and 87 cases showed high expression of phospho-S39-fascin. Survival analysis showed that high expression of fascin was significantly associated with a poor prognosis of the patients with ESCC ( p = 0.004). In contrast, high expression of phospho-S39-fascin correlated significantly with an improved outcome of patients ( p = 0.020). Multivariate analysis showed that both fascin and phospho-S39-fascin were independent prognostic factors. In a combined analysis, the patients with high expression of fascin and low expression of phospho-S39-fascin tumors had a shorter overall survival than those with high expression of both fascin and phospho-S39-fascin tumors (5-year overall survival rate: 28.7% vs 48.3%, p = 0.068). Our results suggest that high expression of fascin correlates with poor outcome and that high expression of phospho-S39-fascin decreases the risk of poor prognosis in ESCC. This manuscript contains online supplemental material at http://www.jhc.org . Please visit this article online to view these materials.</jats:p>","journal":"Journal of Histochemistry &amp; Cytochemistry","year":2010,"id":661674,"datarank":0.515098080672772,"base_score":3.4339872044851463,"endowment":3.4339872044851463,"self_citation_contribution":0.515098080672772,"citation_network_contribution":0.0,"self_endowment_contribution":0.515098080672772,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":507190,"name":"Jin-Hui Shen","orcid":"0000-0001-5871-8363","position":1,"is_corresponding":false},{"id":1727365,"name":"Zhong-Ying Shen","orcid":null,"position":2,"is_corresponding":false},{"id":1727366,"name":"Zhi-Yong Wu","orcid":null,"position":3,"is_corresponding":false},{"id":1727367,"name":"Xiu-E Xu","orcid":null,"position":4,"is_corresponding":false},{"id":1727368,"name":"Jian-Jun Xie","orcid":null,"position":5,"is_corresponding":false},{"id":1727369,"name":"Jian-Yi Wu","orcid":null,"position":6,"is_corresponding":false},{"id":897081,"name":"Qiao Huang","orcid":"0000-0002-9044-2464","position":7,"is_corresponding":false},{"id":1727370,"name":"Xiao-Feng Lu","orcid":null,"position":8,"is_corresponding":false},{"id":1727371,"name":"En-Min Li","orcid":null,"position":9,"is_corresponding":false},{"id":314968,"name":"Li-Yan Xu","orcid":"0000-0002-1618-4292","position":10,"is_corresponding":false},{"id":691260,"name":"Qing Zhao","orcid":"0000-0003-4230-550X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Phosphorylation of Fascin Decreases the Risk of Poor Survival in Patients With Esophageal Squamous Cell Carcinoma","abstract":"<jats:p>Phosphorylation of fascin at serine 39 (phospho-S39-fascin) could inhibit its actin-binding and actin-bundling activities and decrease filopodia formation. However, the relationship between phospho-S39-fascin expression and clinicopathological parameters in tumors is still unknown. Here, Western blot analysis and IHC applied to tissue microarray technology were performed to examine the expression status of non-phosphorylated fascin (fascin) and phospho-S39-fascin and their impacts on the prognosis of patients with esophageal squamous cell carcinoma (ESCC). Fascin and phospho-S39-fascin expressions were tested by cytoplasmic staining. Among the 254 patients, 90 cases showed high expression of fascin and 87 cases showed high expression of phospho-S39-fascin. Survival analysis showed that high expression of fascin was significantly associated with a poor prognosis of the patients with ESCC ( p = 0.004). In contrast, high expression of phospho-S39-fascin correlated significantly with an improved outcome of patients ( p = 0.020). Multivariate analysis showed that both fascin and phospho-S39-fascin were independent prognostic factors. In a combined analysis, the patients with high expression of fascin and low expression of phospho-S39-fascin tumors had a shorter overall survival than those with high expression of both fascin and phospho-S39-fascin tumors (5-year overall survival rate: 28.7% vs 48.3%, p = 0.068). Our results suggest that high expression of fascin correlates with poor outcome and that high expression of phospho-S39-fascin decreases the risk of poor prognosis in ESCC. This manuscript contains online supplemental material at http://www.jhc.org . Please visit this article online to view these materials.</jats:p>","is_dataset_classified":null,"base_score":3.4339872044851463,"endowment":3.4339872044851463,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20713986","pmcid":"PMC2958140","openalex_id":"https://openalex.org/W2168145925","authors":[],"funders":[],"total_grants":0,"fwci":0.6182,"citation_percentile":0.65806923,"influential_citations":0,"citation_trend":[{"year":2012,"count":2},{"year":2013,"count":2},{"year":2014,"count":5},{"year":2015,"count":2},{"year":2016,"count":2},{"year":2017,"count":5},{"year":2018,"count":2},{"year":2020,"count":1},{"year":2021,"count":3},{"year":2022,"count":4},{"year":2024,"count":1}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://journals.sagepub.com/doi/pdf/10.1369/jhc.2010.955765","host_type":"journal"},{"url":"https://journals.sagepub.com/doi/pdf/10.1369/jhc.2010.955765","host_type":"publisher"},{"url":"https://journals.sagepub.com/doi/full-xml/10.1369/jhc.2010.955765","host_type":"publisher"},{"url":"https://doi.org/10.1369/jhc.2010.955765","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20713986","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2958140","host_type":"repository"},{"url":"http://journals.sagepub.com/doi/pdf/10.1369/jhc.2010.955765","host_type":"Unpaywall"}],"fields_of_study":["Cellular Mechanics and Interactions","Cell Adhesion Molecules Research","Proteoglycans and glycosaminoglycans research"],"mesh_terms":["Adult","Aged","Animals","Antibody Specificity","Carcinoma, Squamous Cell","Carrier Proteins","Esophageal Neoplasms","Female","Humans","Male","Microfilament Proteins","Middle Aged","Phosphoproteins","Phosphorylation","Prognosis","Risk","Serine","Gene Expression Regulation, Neoplastic","Survival Analysis","Cell Line, Tumor"],"keywords":["Fascin","Immunohistochemistry","Filopodia","Internal medicine","Oncology","Cancer research","Biology","Medicine","Actin","Cell biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"No poverty"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T11:26:00.161711Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}